GAITHERSBURG, Md.--(BUSINESS WIRE)--Wellstat Therapeutics Corporation announced today that it has granted U.S. marketing rights for the company’s investigational drug uridine triacetate to the specialist healthcare company BTG International Inc. for use as a potential treatment for accidental overexposure to the chemotherapy drug fluorouracil (5-FU) due to dosing errors or impaired clearance of 5-FU from the body. Wellstat has retained commercialization rights for treatment of 5-FU overexposure outside of the U.S. and for all other potential uses of uridine triacetate.
